Cooper Companies Valuation
Is 0I3I undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0I3I when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0I3I ($99.45) is trading below our estimate of fair value ($171.6)
Significantly Below Fair Value: 0I3I is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0I3I?
Key metric: As 0I3I is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0I3I's PE Ratio? | |
|---|---|
| PE Ratio | 55.2x |
| Earnings | US$359.30m |
| Market Cap | US$19.89b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6x |
| Enterprise Value/EBITDA | 22.2x |
| PEG Ratio | 2.4x |
Price to Earnings Ratio vs Peers
How does 0I3I's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 37.2x | ||
CTEC ConvaTec Group | 41.9x | 20.6% | UK£5.1b |
AMS Advanced Medical Solutions Group | 39.8x | 23.0% | UK£443.2m |
TSTL Tristel | 32.3x | 17.5% | UK£209.7m |
SN. Smith & Nephew | 34.7x | 22.5% | UK£8.4b |
0I3I Cooper Companies | 55.2x | 23.0% | US$19.9b |
Price-To-Earnings vs Peers: 0I3I is expensive based on its Price-To-Earnings Ratio (55.2x) compared to the peer average (37.2x).
Price to Earnings Ratio vs Industry
How does 0I3I's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0I3I is expensive based on its Price-To-Earnings Ratio (55.2x) compared to the European Medical Equipment industry average (29.9x).
Price to Earnings Ratio vs Fair Ratio
What is 0I3I's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 55.2x |
| Fair PE Ratio | 46x |
Price-To-Earnings vs Fair Ratio: 0I3I is expensive based on its Price-To-Earnings Ratio (55.2x) compared to the estimated Fair Price-To-Earnings Ratio (46x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$99.45 | US$114.29 +14.9% | 9.2% | US$130.00 | US$92.12 | n/a | 14 |
| Nov ’25 | US$105.90 | US$114.29 +7.9% | 9.2% | US$130.00 | US$92.12 | n/a | 14 |
| Oct ’25 | US$109.44 | US$113.51 +3.7% | 8.9% | US$130.00 | US$92.12 | n/a | 14 |
| Sep ’25 | US$104.64 | US$114.08 +9.0% | 8.0% | US$125.00 | US$95.00 | n/a | 13 |
| Aug ’25 | US$94.05 | US$111.46 +18.5% | 7.9% | US$125.00 | US$95.00 | n/a | 13 |
| Jul ’25 | US$85.88 | US$109.72 +27.8% | 8.6% | US$125.00 | US$95.00 | n/a | 14 |
| Jun ’25 | US$93.29 | US$108.16 +15.9% | 10.0% | US$125.00 | US$86.25 | n/a | 15 |
| May ’25 | US$89.10 | US$107.90 +21.1% | 9.6% | US$125.00 | US$86.25 | n/a | 16 |
| Apr ’25 | US$101.67 | US$107.40 +5.6% | 9.5% | US$125.00 | US$86.25 | n/a | 16 |
| Mar ’25 | US$102.20 | US$102.81 +0.6% | 9.7% | US$116.00 | US$84.30 | n/a | 16 |
| Feb ’25 | US$93.75 | US$97.85 +4.4% | 8.2% | US$110.00 | US$84.25 | n/a | 16 |
| Jan ’25 | US$94.57 | US$96.57 +2.1% | 8.2% | US$107.50 | US$84.25 | n/a | 16 |
| Dec ’24 | US$83.94 | US$98.10 +16.9% | 7.6% | US$107.50 | US$85.75 | n/a | 15 |
| Nov ’24 | US$78.25 | US$98.25 +25.6% | 7.6% | US$107.50 | US$85.75 | US$105.90 | 15 |
| Oct ’24 | US$80.67 | US$100.57 +24.7% | 7.6% | US$110.00 | US$86.25 | US$109.44 | 14 |
| Sep ’24 | US$90.32 | US$101.16 +12.0% | 7.3% | US$110.00 | US$86.25 | US$104.64 | 14 |
| Aug ’24 | US$96.96 | US$100.38 +3.5% | 8.3% | US$110.00 | US$81.25 | US$94.05 | 14 |
| Jul ’24 | US$95.44 | US$99.50 +4.3% | 7.8% | US$107.75 | US$81.25 | US$85.88 | 14 |
| Jun ’24 | US$93.74 | US$97.43 +3.9% | 9.2% | US$107.50 | US$80.00 | US$93.29 | 13 |
| May ’24 | US$95.02 | US$93.46 -1.6% | 8.0% | US$107.50 | US$80.00 | US$89.10 | 12 |
| Apr ’24 | US$93.15 | US$88.65 -4.8% | 8.5% | US$97.50 | US$70.00 | US$101.67 | 12 |
| Mar ’24 | US$80.90 | US$86.90 +7.4% | 9.6% | US$96.25 | US$70.00 | US$102.20 | 12 |
| Feb ’24 | US$87.34 | US$86.90 -0.5% | 9.6% | US$96.25 | US$70.00 | US$93.75 | 12 |
| Jan ’24 | US$82.52 | US$85.21 +3.3% | 8.4% | US$93.75 | US$70.00 | US$94.57 | 12 |
| Dec ’23 | US$80.87 | US$84.43 +4.4% | 8.5% | US$92.50 | US$70.00 | US$83.94 | 10 |
| Nov ’23 | US$68.07 | US$83.55 +22.7% | 9.2% | US$93.75 | US$70.00 | US$78.25 | 10 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Guerbet
€341.1m
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
0ELV
€27.05
7D
-9.8%
1Y
51.3%
Fagron
€1.4b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
0HNZ
€18.61
7D
-1.4%
1Y
6.7%
Axogen
US$548.8m
Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.
0HKD
US$12.49
7D
1.2%
1Y
112.1%